remedi4all.org
Meaningful patient participation is a core element of iDR26. Below, patients and patient organisations share their experiences of attending last year’s conference.
👉 More information here: https://loom.ly/Ff53lz0
Meaningful patient participation is a core element of iDR26. Below, patients and patient organisations share their experiences of attending last year’s conference.
👉 More information here: https://loom.ly/Ff53lz0
🌐Rare Diseases
🔍Discovery
💼Industry
👥Community
Interested in learning more about these key areas in drug repurposing? Join us on 12-13 May in Brussels (limited early bird tickets)➡️ https://loom.ly/9dw7qdk
🌐Rare Diseases
🔍Discovery
💼Industry
👥Community
Interested in learning more about these key areas in drug repurposing? Join us on 12-13 May in Brussels (limited early bird tickets)➡️ https://loom.ly/9dw7qdk
🔗 Read the article here: https://loom.ly/9kv7-MY
🔗 Read the article here: https://loom.ly/9kv7-MY
Two annotation workflows (KNIME + Python/Neo4j) help extract, harmonise & explore chemical and bioactivity data across >5000 compounds for drug repurposing!
🔗Read the open access article in Database➡️ https://loom.ly/nboSzbk
Two annotation workflows (KNIME + Python/Neo4j) help extract, harmonise & explore chemical and bioactivity data across >5000 compounds for drug repurposing!
🔗Read the open access article in Database➡️ https://loom.ly/nboSzbk
Read the full article here➡️ https://loom.ly/nYdimM0
Read the full article here➡️ https://loom.ly/nYdimM0
🔬 Poster Session – Deadline: 10 January 2026
⚡ Lightning Talks - Deadline: 27 February 2026
Submit your application here: https://loom.ly/XvNoRTM
🔬 Poster Session – Deadline: 10 January 2026
⚡ Lightning Talks - Deadline: 27 February 2026
Submit your application here: https://loom.ly/XvNoRTM
Funding is provided for selected participants.
📝 Apply by 14 Jan here: https://loom.ly/4QEaVoc
Funding is provided for selected participants.
📝 Apply by 14 Jan here: https://loom.ly/4QEaVoc
Nitisinone went from an herbicide to an approved treatment for two rare diseases (HT-1 & AKU). A remarkable example of #DrugRepurposing powered by science and patient advocacy.
➡️ https://loom.ly/4Qp4-yg
Nitisinone went from an herbicide to an approved treatment for two rare diseases (HT-1 & AKU). A remarkable example of #DrugRepurposing powered by science and patient advocacy.
➡️ https://loom.ly/4Qp4-yg
Join a diverse community of stakeholders, collaborating to strengthen the drug repurposing ecosystem and navigate the future of cutting-edge science to maximise patient benefit.
🔗 More details: https://loom.ly/ToR-dtw
Join a diverse community of stakeholders, collaborating to strengthen the drug repurposing ecosystem and navigate the future of cutting-edge science to maximise patient benefit.
🔗 More details: https://loom.ly/ToR-dtw
☑️Highlights: concierge support, funding marketplace, value assessment tool, webinars, and policy/patient engagement.
👥More collaboration ahead!
☑️Highlights: concierge support, funding marketplace, value assessment tool, webinars, and policy/patient engagement.
👥More collaboration ahead!
Following a highly successful inaugural edition, applications are now open for the 2026 REMEDi4ALL Academic Bootcamp at Wellcome Genome Campus (Cambridge, UK)!
🗓️Dates: 11–12 March 2026
➡️Apply here by 14 Jan: https://loom.ly/4QEaVoc
Following a highly successful inaugural edition, applications are now open for the 2026 REMEDi4ALL Academic Bootcamp at Wellcome Genome Campus (Cambridge, UK)!
🗓️Dates: 11–12 March 2026
➡️Apply here by 14 Jan: https://loom.ly/4QEaVoc
More➡️ https://loom.ly/J3ocQH4
More➡️ https://loom.ly/J3ocQH4
Follow #VAMWeek 2025 to find out more!
Follow #VAMWeek 2025 to find out more!
🔹 Share your experiences and perspectives in discussions shaping the future of drug repurposing
🔹 Hear directly from researchers, clinicians and regulators
Register for iDR26 here: https://loom.ly/Qo4ko8s
🔹 Share your experiences and perspectives in discussions shaping the future of drug repurposing
🔹 Hear directly from researchers, clinicians and regulators
Register for iDR26 here: https://loom.ly/Qo4ko8s
Early career researchers from across Europe gathered near Montserrat to tackle real-world challenges in drug repurposing for rare neurodevelopmental disorders.
Catch the highlights ➡️https://loom.ly/N6tXCHs
Early career researchers from across Europe gathered near Montserrat to tackle real-world challenges in drug repurposing for rare neurodevelopmental disorders.
Catch the highlights ➡️https://loom.ly/N6tXCHs
Submit your abstract for the 🔬 Poster Session or apply for a ⚡ Lightning Talk here: https://loom.ly/XvNoRTM
👉 Discover our bursaries for patients & patient groups: https://loom.ly/Ff53lz0
Submit your abstract for the 🔬 Poster Session or apply for a ⚡ Lightning Talk here: https://loom.ly/XvNoRTM
👉 Discover our bursaries for patients & patient groups: https://loom.ly/Ff53lz0
🎬Register via the REMEDi4ALL Digital Academy for the recording: https://loom.ly/IeBJ9No
🎬Register via the REMEDi4ALL Digital Academy for the recording: https://loom.ly/IeBJ9No
Alicia Soler, Heleen van der Meer and Pan Pantziarka will introduce REMEDi4ALL to 30+ charity funders, exploring how to advance drug repurposing together.
Register: https://loom.ly/ZkaHBcA
Alicia Soler, Heleen van der Meer and Pan Pantziarka will introduce REMEDi4ALL to 30+ charity funders, exploring how to advance drug repurposing together.
Register: https://loom.ly/ZkaHBcA
REMEDi4ALL recently co-organised a Multistakeholder Meeting with EURORDIS to explore how #DrugRepurposing can address these needs.
👉 Meeting summary: https://loom.ly/3u2fS7g
REMEDi4ALL recently co-organised a Multistakeholder Meeting with EURORDIS to explore how #DrugRepurposing can address these needs.
👉 Meeting summary: https://loom.ly/3u2fS7g
Join us 12&13 May in Brussels to explore how repurposing can help deliver treatments for patients worldwide.
🎟️ Learn more: https://loom.ly/ToR-dtw
Join us 12&13 May in Brussels to explore how repurposing can help deliver treatments for patients worldwide.
🎟️ Learn more: https://loom.ly/ToR-dtw
Discover how IP strategies accelerate drug repurposing projects with LifeArc, King’s College London & Beacon for Rare Diseases.
🔗 https://loom.ly/bG6rhso
Discover how IP strategies accelerate drug repurposing projects with LifeArc, King’s College London & Beacon for Rare Diseases.
🔗 https://loom.ly/bG6rhso
Partners from Syreon Research Institute represented REMEDi4ALL at #ISPOREurope2025 in Glasgow — sharing insights on policy barriers to drug repurposing and patient engagement in early HTA for Losartan in Osteogenesis Imperfecta.
#DrugRepurposing #HTA
Partners from Syreon Research Institute represented REMEDi4ALL at #ISPOREurope2025 in Glasgow — sharing insights on policy barriers to drug repurposing and patient engagement in early HTA for Losartan in Osteogenesis Imperfecta.
#DrugRepurposing #HTA
Join a global community driving the future of drug repurposing.
💡 Cutting-edge science
🤝 Collaboration
⚖️ Policy & access
🔬 Real-world case studies
Connect, share, and shape faster, more affordable treatments.
🔗 https://remedi4all.org/iDR26
Join a global community driving the future of drug repurposing.
💡 Cutting-edge science
🤝 Collaboration
⚖️ Policy & access
🔬 Real-world case studies
Connect, share, and shape faster, more affordable treatments.
🔗 https://remedi4all.org/iDR26
Findings will guide future reforms to improve access to repurposed medicines.
📘More here: https://loom.ly/zCuz-oY
Findings will guide future reforms to improve access to repurposed medicines.
📘More here: https://loom.ly/zCuz-oY